60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Price & Analysis
60 Degrees Pharmaceuticals, Inc. (SXTP) fell 0.67% to USD 1.48 as of July 25, 2026 at 05:23 UTC, according to Nexqual real-time market data.
SXTP last closed at USD 1.49; the session ranged USD 1.42–1.56 on volume of 58,131 shares. Market capitalization is $3.94M, with a 52-week range of USD 1.22–8.62 (NCM). Source: Nexqual, July 25, 2026 at 05:23 UTC.
Key Statistics (as of July 25, 2026 at 05:23 UTC)
| Price | USD 1.48 |
|---|---|
| Change | ▼ 0.67% (down) |
| Previous Close | USD 1.49 |
| Open | USD 1.52 |
| Day Range | USD 1.42 – 1.56 |
| 52-Week Range | USD 1.22 – 8.62 |
| Volume | 58,131 shares |
| Market Cap | $3.94M |
| Exchange | NCM |
Technical Analysis (SXTP)
Nexqual's technical model rates SXTP "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:23 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.7 (neutral) |
| vs SMA50 | Below (USD 1.53) |
| MACD | -0.02 (negative) |
Analyst Ratings (SXTP)
Wall Street analysts rate SXTP "None" based on 1 analysts, with a mean price target of USD 3.7 (range USD 3.7–3.7), per Nexqual as of July 25, 2026 at 05:23 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 3.7 |
| High Target | USD 3.7 |
| Low Target | USD 3.7 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (SXTP)
| EPS Estimate | USD -0.89 |
|---|---|
| Revenue Estimate | $185,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.21 vs est -0.99 ▼ miss |
| 2025-12-31 | USD -8.17 vs est -2 ▼ miss |
| 2025-09-30 | USD -2.53 vs est -1.84 ▼ miss |
| 2025-06-30 | USD -4.33 vs est -4.96 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:23 UTC.
Financials & Fundamentals (SXTP)
| Total Revenue | $1.31M |
|---|---|
| Revenue Growth (YoY) | -36.80% |
| Gross Margin | -113.78% |
| Operating Margin | -1292.45% |
| Profit Margin | +0.00% |
| ROE | -172.82% |
| Debt / Equity | 3.2 |
| Current Ratio | 3.34 |
| Total Cash | $3.34M |
| Total Debt | $151,969 |
| Free Cash Flow | $-5.39M |
Source: Nexqual, July 25, 2026 at 05:23 UTC.
Financial Health Score (SXTP)
Nexqual rates 60 Degrees Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 05:23 UTC.
| Growth | Strong — Revenue +65% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $3M cash, no debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -173%, ROA -77.9% |
Ownership (SXTP)
| Insider Ownership | +0.88% |
|---|---|
| Institutional Ownership | +9.60% |
| Shares Outstanding | 2.66M |
| Float | 2.43M |
| Short % of Float | +5.55% |
Source: Nexqual, July 25, 2026 at 05:23 UTC.
Leadership (SXTP)
60 Degrees Pharmaceuticals, Inc. is led by Geoffrey Stuart Dow (age 51), Chairman, CEO & President, per Nexqual as of July 25, 2026 at 05:23 UTC.
| Chairman, CEO & President | Geoffrey Stuart Dow (age 51) |
|---|---|
| CFO & Treasurer | Tyrone Miller (age 50) |
Major Backers & Investors (SXTP)
Notable institutional backers of 60 Degrees Pharmaceuticals, Inc. include Kathmere Capital Management, Llc, UBS Group AG, Fidelity, according to Nexqual as of July 25, 2026 at 05:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kathmere Capital Management, Llc | 5.44% |
| UBS Group AG | 1.18% |
| Fidelity | 0.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.61% |
Source: Nexqual, July 25, 2026 at 05:23 UTC.
From 60 Degrees Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- 60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
- It offers Arakoda for malaria prevention treatment.
- The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TRNR | Interactive Strength Inc. | USD 3.17 | ▼ 0.94% |
| MGRX | Mangoceuticals, Inc. | USD 0.52 | ▲ 1.9% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.12 | ▼ 1.69% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.32 | ▲ 4.76% |
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:23 UTC. This page is informational and not investment advice.